Recent News

• 06.30.2026 - Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
• 06.30.2026 - Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
• 06.30.2026 - Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
• 06.15.2026 - Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
• 06.15.2026 - Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
• 06.15.2026 - Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
• 05.29.2026 - Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
• 05.29.2026 - Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
• 05.13.2026 - Aptose Reports First Quarter 2026 Results
• 05.13.2026 - Aptose Reports First Quarter 2026 Results

Recent Filings

• 07.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2026 - 15-12G Securities registration termination [Section 12(g)]
• 07.01.2026 - SC 13E3/A Going private transaction by certain issuers
• 07.01.2026 - 8-K Current report
• 07.01.2026 - 8-K Current report
• 07.01.2026 - EX-99.1 EX-99.1
• 07.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2026 - 4 Statement of changes in beneficial ownership of securities